Metrion and LifeArc extend collaboration on neurological target

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/ClaudioVentrella)
(Image: Getty/ClaudioVentrella)

Related tags: Metrion Biosciences, LifeArc, Neurology, Neuroscience

After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.

Metrion Biosciences, a contract research organization (CRO) and drug discovery company, and LifeArc, a UK-based medical research charity, partnered in January 2019​ to work on a small molecule neuroscience drug discovery program.

More specifically, the joint project aims to identify novel selective small molecule modulators of a specific ion channel target, which human patient gene association studies have identified as likely to be involved in neurological pathogenesis.

Under the initial agreement, LifeArc has responsibility for all new chemical syntheses, with Metrion conducting ion channel screening.

Moreover, Metrion has provided support for LifeArc’s medicinal chemistry target optimization via its suite of drug discovery assays, including automated and conventional electrophysiology, translational neuroscience, and cardiac safety profiling assays.

With the first year of collaboration almost complete, the companies agreed to extend their initial agreement for another 12-month period, after having seen ‘success’ in their research and ‘achievement of mutually agreed criteria’, according to Metrion.

As a result of this success during the initial phase, potent and efficacious hit compounds have been identified through a ‘robust’ screening cascade, with the collaboration now progressing into the ‘hit-to-lead’ optimization phase, Metrion announced.

Therefore, Metrion will continue to support target optimization by utilizing its capabilities in developing validated screening assays for use against specific neuronal ion channels, or in a range of translational phenotypic disease-relevant assays, to explore the potential treatments’ mechanism of action.

Related news

Show more

Related products

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars